Tat-NR2B9c TFA Tat-NR2Bct TFA; NA-1 TFA|cas:1834571-04-8|西域试剂

Tat-NR2B9c TFA Tat-NR2Bct TFA; NA-1 TFA,99.67%

产品编号：Bellancom-P0117A| CAS NO：1834571-04-8| 分子式：C₁₀₅H₁₈₈N₄₂O₃₀.C₂HF₃O₂| 分子量：2632.90

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-P0117A	￥700.00	杭州北京（现货）
Bellancom-P0117A	￥1800.00	杭州北京（现货）
Bellancom-P0117A	￥2800.00	杭州北京（现货）
Bellancom-P0117A	￥5500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Tat-NR2B9c TFA Tat-NR2Bct TFA; NA-1 TFA

产品介绍

Tat-NR2B9c TFA (Tat-NR2Bct TFA) 是一种 PSD-95 的抑制剂，抑制 PSD-95d2 (PSD-95 PDZ domain 2) 和 PSD-95d1 的 EC₅₀ 分别为 6.7 nM 和 670 nM。Tat-NR2B9c TFA 扰乱了 PSD-95/NMDAR 的相互作用，抑制 PSD-95 和 NR2A 和 NR2B 结合的 IC₅₀ 值分别为 0.5 μM 和 8 μM。Tat-NR2B9c TFA 还能抑制神经元一氧化氮合酶 (nNOS)/PSD-95 相互作用，具有神经保护作用。

生物活性

Tat-NR2B9c TFA (Tat-NR2Bct TFA) is a postsynaptic density-95 (PSD-95) inhibitor, with EC₅₀ values of 6.7 nM and 670 nM for PSD-95d2 (PSD-95 PDZ domain 2) and PSD-95d1, respectively. Tat-NR2B9c TFA disrupts the PSD-95/NMDAR interaction, inhibiting NR2A and NR2B binding to PSD-95 with IC₅₀ values of 0.5 μM and 8 μM, respectively. Tat-NR2B9c TFA also inhibits neuronal nitric oxide synthase (nNOS)/PSD-95 interaction, and possesses neuroprotective efficacy.

体外研究

Tat-NR2B9c is a PSD-95 inhibitor, with an EC₅₀ of 6.7 nM for PSD-95d2, representing a >100-fold higher affinity for this domain than for PSD-95d1 (EC₅₀, 0.67 μM). Tat-NR2B9c inhibits NMDAR2A, NMDAR2B, and NMDAR2C binding to PSD-95, with IC₅₀s of 0.5 μM, ∼8 μM, and 0.75 μM, respectively.
Tat-NR2B9c also blocks the interaction between PSD-95 and nNOS with an IC₅₀ of ∼0.2 μM.
Tat-NR2B9c reduces association of PSD-95 with GluN2B by ∼50% in the YAC128 striatum, decreases NMDA-induced p38 activation in YAC128 striatal tissue, but shows no effect on the NMDA-induced JNK activation.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

Tat-NR2B9c (10 nmol/g, i.v.) reduces infarction volume of male C57BL/6 mice, but has no effect at 3 nmol/g.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

Tat-NR2B9c (10 nmol/g, i.v.) reduces infarction volume of male C57BL/6 mice, but has no effect at 3 nmol/g.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

性状

Solid

溶解性数据

In Vitro:

H₂O : ≥ 50 mg/mL (18.99 mM)

* "≥" means soluble, but saturation unknown.

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	0.3798 mL	1.8990 mL	3.7981 mL
5 mM	0.0760 mL	0.3798 mL	0.7596 mL
10 mM	0.0380 mL	0.1899 mL	0.3798 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶